Sieswerda, E;
Boer, M.G.J. de;
Bonten, M. M. J;
Boersma, W. G;
Jonkers, R. E;
Aleva, R. M;
Kullberg, B. J;
Schouten, J. A;
van de Garde, E.M. W;
Verheij, T. J;
van der Eerden, M. M;
Prins, J. M;
Wiersinga, W. J.
The Dutch Working Party on Antibiotic Policy constituted a multidisciplinary expert committee to provide evidence-based recommendation for the use of antibacterial therapy in hospitalized adults with a respiratory infection and suspected or proven 2019 Coronavirus disease (COVID-19). We performed a liter...
Jin, Ying-Hui;
Zhan, Qing-Yuan;
Peng, Zhi-Yong;
Ren, Xue-Qun;
Yin, Xun-Tao;
Cai, Lin;
Yuan, Yu-Feng;
Yue, Ji-Rong;
Zhang, Xiao-Chun;
Yang, Qi-Wen;
Ji, Jianguang;
Xia, Jian;
Li, Yi-Rong;
Zhou, Fu-Xiang;
Gao, Ya-Dong;
Yu, Zhui;
Xu, Feng;
Tu, Ming-Li;
Tan, Li-Ming;
Yang, Min;
Chen, Fang;
Zhang, Xiao-Ju;
Zeng, Mei;
Zhu, Yu;
Liu, Xin-Can;
Yang, Jian;
Zhao, Dong-Chi;
Ding, Yu-Feng;
Hou, Ning;
Wang, Fu-Bing;
Chen, Hao;
Zhang, Yong-Gang;
Li, Wei;
Chen, Wen;
Shi, Yue-Xian;
Yang, Xiu-Zhi;
Wang, Xue-Jun;
Zhong, Yan-Jun;
Zhao, Ming-Juan;
Li, Bing-Hui;
Ma, Lin-Lu;
Zi, Hao;
Wang, Na;
Wang, Yun-Yun;
Yu, Shao-Fu;
Li, Lu-Yao;
Huang, Qiao;
Weng, Hong;
Ren, Xiang-Ying;
Luo, Li-Sha;
Fan, Man-Ru;
Huang, Di;
Xue, Hong-Yang;
Yu, Lin-Xin;
Gao, Jin-Ping;
Deng, Tong;
Zeng, Xian-Tao;
Li, Hong-Jun;
Cheng, Zhen-Shun;
Yao, Xiaomei;
Wang, Xing-Huan.
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness,
coronavirus disease 2019 (COVID-19), affecting more than seventeen million people around the world. Diagnosis
and treatment guidelines for clinicians caring for patients are needed. In the ...
Chimioprévention/méthodes,
Infections à coronavirus/diagnostic,
Infections à coronavirus/traitement médicamenteux,
Pneumopathie virale/diagnostic,
Pneumopathie virale/traitement médicamenteux,
Pandémies/prévention et contrôle,
Betacoronavirus/effets des médicaments et des substances chimiques,
Pratique factuelle/méthodes,
Antirétroviraux/usage thérapeutique,
Lopinavir/usage thérapeutique,
Chloroquine/usage thérapeutique,
Récepteurs à l'interleukine-6/usage thérapeutique,
Hydroxychloroquine/usage thérapeutique,
Plasma sanguin/immunologie
Rochwerg, Bram;
Agarwal, Arnav;
Zeng, Linan;
Leo, Yee-Sin;
Appiah, John Adabie;
Agoritsas, Thomas;
Bartoszko, Jessica;
Brignardello-Petersen, Romina;
Ergan, Begum;
Ge, Long;
Geduld, Heike;
Gershengorn, Hayley B;
Manai, Hela;
Huang, Minhua;
Lamontagne, François;
Kanda, Seema;
Kawano-Dourado, Leticia;
Kurian, Linda;
Kwizera, Arthur;
Murthy, Srinivas;
Qadir, Nida;
Siemieniuk, Reed;
Silvestre, Maria Asuncion;
Vandvik, Per Olav;
Ye, Zhikang;
Zeraatkar, Dena;
Guyatt, Gordon.
Clinical question: What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020.Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19. Aft...
A potentially severe acute respiratory infection caused by the novel coronavirus severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2).[1] The clinical presentation is generally that of a respiratory infection
with a symptom severity ranging from a mild common cold-like illness, to a severe viral ...
Betacoronavirus/pathogénicité,
Infections à coronavirus/imagerie diagnostique,
Infections à coronavirus/complications,
Infections à coronavirus/traitement médicamenteux,
Pneumopathie virale/imagerie diagnostique,
Pneumopathie virale/traitement médicamenteux,
Pneumopathie virale/complications,
Pandémies/statistiques et données numériques,
Aggravation transitoire des symptômes,
Groupes à Risque,
Chine/épidémiologie,
Pneumonie associée aux soins/diagnostic,
Personnel de santé/organisation et administration,
État de porteur sain/transmission,
Transmission verticale de maladie infectieuse/prévention et contrôle
Moores, Lisa K;
Tritschler, Tobias;
Brosnahan, Shari;
Carrier, Marc;
Collen, Jacob F;
Doerschug, Kevin;
Holley, Aaron B;
Jimenez, David;
Gal, Gregoire Le;
Rali, Parth;
Wells, Philip.
Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and VTE. This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of...
Falavigna, Maicon;
Colpani, Verônica;
Stein, Cinara;
Azevedo, Luciano César Pontes;
Bagattini, Ângela Maria;
Brito, Gabriela Vilela de;
Chatkin, José Miguel;
Cimerman, Sérgio;
Corradi, Mirian de Freitas Dal Ben;
Cunha, Clóvis Arns da;
Medeiros, Flávia Cordeiro de;
Oliveira Júnior, Haliton Alves de;
Fritscher , Leandro Genehr;
Gazzana, Marcelo Basso;
Graf, Débora Dalmas;
Marra, Lays Pires;
Matuoka , Jéssica Yumi;
Nunes, Michelle Silva;
Pachito, Daniela Vianna;
Pagano, Cássia Garcia Moraes;
Parreira, Patrícia do Carmo Silva;
Riera, Rachel;
Silva Júnior, Amilton;
Tavares, Bruno de Melo;
Zavascki, Alexandre Prehn;
Rosa, Régis Goulart;
Dal-Pizzol, Felipe.
Different therapies are currently used, considered, or proposed for the treatment of COVID-19; for many of those therapies, no appropriate assessment of effectiveness and safety was performed. This document aims to provide scientifically available evidence-based information in a transparent interpretatio...
Infections à coronavirus/traitement médicamenteux,
Aminoquinoléines/usage thérapeutique,
Oséltamivir/usage thérapeutique,
Lopinavir/usage thérapeutique,
Ritonavir/usage thérapeutique,
Hormones corticosurrénaliennes/usage thérapeutique,
Héparine/usage thérapeutique,
Antibactériens/usage thérapeutique,
Betacoronavirus/effets des médicaments et des substances chimiques,
Pneumopathie virale/traitement médicamenteux,
Pandémies/prévention et contrôle
The purpose of this guideline is to ensure the best antibiotic management of suspected or confirmed bacterial pneumonia in adults in hospital during the COVID‑19 pandemic. This includes people presenting to hospital with moderate to severe community-acquired pneumonia and people who develop pneumonia w...
China has managed to control the coronavirus disease (COVID-19) with confinement measurements and treatment strategies, while other countries are struggling to contain the spread. This study discussesthe guidelines related to COVID-19 in China in order to provide important references for other countries
...
Betacoronavirus/effets des médicaments et des substances chimiques,
Pneumopathie virale/épidémiologie,
Infections à coronavirus/épidémiologie,
Chine/épidémiologie,
Pandémies/prévention et contrôle,
Pandémies/statistiques et données numériques,
Surveillance épidémiologique,
Gestion de l'information en santé/méthodes,
Interférons/usage thérapeutique,
Lopinavir/usage thérapeutique,
Ritonavir/usage thérapeutique,
Ribavirine/usage thérapeutique,
Chloroquine/usage thérapeutique,
Infections à coronavirus/traitement médicamenteux,
Pneumopathie virale/traitement médicamenteux
Bhimraj, Adarsh;
Morgan, Rebecca L;
Shumaker, Amy Hirsch;
Lavergne, Valery;
Baden, Lindsey;
Cheng, Vincent Chi-Chung;
Edwards, Kathryn M;
Gandhi, Rajesh;
Muller, William J;
O’Horo, John C;
Shoham, Shmuel;
Murad, M. Hassan;
Mustafa, Reem A;
Sultan, Shahnaz;
Falck-Ytter, Yngve.
Develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19....
The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic and best use of NHS resources. We have withdrawn our guideline on diagnosing and managing pneumonia in adults until further notice....
